AKBA · XBRL financial data

Akebia Therapeutics financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (AKBA's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	295	214	292	195	160	236
Cost of revenue	296	153	86	74	63	39
Research and development	218	148	130	63	38	62
Selling, general and administrative	154	174	139	100	107	107
Total operating expenses	376	326	288	167	147	173
Operating income (loss)	(376)	(265)	(81)	(46)	(50)	23
Other income (expense)	2	2	3	1	0	0
Income tax expense (benefit)	0	0	0	0	0	2
Net income (loss)	(383)	(283)	(94)	(52)	(69)	(5)
Earnings per share, basic USD per share	(2.78)	(1.70)	(0.52)	(0.28)	(0.33)	(0.02)
Earnings per share, diluted USD per share	(2.78)	(1.70)	(0.52)	(0.28)	(0.33)	(0.02)
Weighted average shares, basic millions of shares	138	166	183	187	211	257
Weighted average shares, diluted millions of shares	138	166	183	187	211	257

Fiscal years (AKBA's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	229	150	90	43	52	185
Accounts receivable	27	51	40	39	34	47
Inventory	61	38	22	16	16	16
Prepaid and other current assets	15	33	33	20	11	5
Total current assets	371	272	185	118	114	253
Property and equipment, net	9	7	5	4	2	1
Right-of-use asset	27	34	29	12	8	4
Goodwill	55	55	59	59	59	59
Total assets	644	526	356	242	221	377
Accounts payable	41	34	18	15	15	21
Accrued liabilities	131	104	76	68	63	122
Current portion of long-term debt	0	98	32	18	0	0
Total current liabilities	187	256	130	100	81	163
Long-term debt	96	0	34	17	39	48
Lease liability, non-current	25	34	29	9	4	0
Total liabilities	397	449	351	272	270	344
Accumulated deficit	(1,178)	(1,460)	(1,557)	(1,609)	(1,678)	(1,684)
Total stockholders' equity	248	76	5	(31)	(49)	33
Total liabilities and equity	644	526	356	242	221	377
Common shares outstanding (cover page) millions of shares	154	181	184	209	236	268

Fiscal years (AKBA's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(383)	(283)	(94)	(52)	(69)	(5)
Stock-based compensation	24	23	18	9	8	11
Depreciation and amortization	2	2	2	—	—	—
Net cash from operating activities	(110)	(253)	(73)	(23)	(41)	68
Purchases of property and equipment	0	0	0	0	0	0
Net cash from investing activities	(40)	40	(0)	0	(0)	(8)
Proceeds from long-term debt	20	0	0	—	—	—
Net cash from financing activities	232	134	15	(25)	50	73
Net change in cash	81	(79)	(59)	(49)	9	133

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Akebia Therapeutics	156	49	3.5*	277.1M	—	Q2 FY26 10-QJun 30, 2026
Viridian Therapeutics	165	not reported	(105)*	113.3M	9.3 quarters	Q2 FY26 10-QJun 30, 2026
Collegium Pharmaceutical	129	200	71*	32.6M	—	Q2 FY26 10-QJun 30, 2026
Ardelyx	46	128	2.2*	251.4M	—	Q3 FY26 10-QSep 30, 2026
Neogen	172	223	13	218.3M	—	Q1 FY27 10-QAug 31, 2026
CorMedix	257	102	86*	77.9M	—	Q2 FY26 10-QJun 30, 2026
Aurinia Pharmaceuticals	46	84	46*	134.0M	—	Q3 FY26 10-QSep 30, 2026
Harrow	84	71	(9.8)*	37.5M	8.6 quarters	Q2 FY26 10-QJun 30, 2026
Novavax	191	57	(73)*	164.9M	9.9 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.